4.2 Article

Estimation of sensitivity and specificity of several Trypanosoma cruzi antibody assays in blood donors in Argentina

Journal

TRANSFUSION
Volume 49, Issue 11, Pages 2352-2358

Publisher

WILEY
DOI: 10.1111/j.1537-2995.2009.02301.x

Keywords

-

Categories

Funding

  1. Blood Systems Research Institute [NHLB IK24-HL-75036]
  2. University of California, San Francisco, Center for AIDS Prevention Studies (U.S. National Institute of Mental Health (NIMH) [P30 MH062246]
  3. International Traineeships in AIDS Prevention Studies [R25MH064712]
  4. AIDS International Training in Research Program [D43TW00003]

Ask authors/readers for more resources

BACKGROUND: The absence of a gold standard test for Trypanosoma cruzi antibodies represents a problem not only for the evaluation of screening tests, but also for appropriate blood donor counseling. The aim of this study was to estimate the sensitivity and specificity of multiple blood donor screening tests for T. cruzi antibodies in Argentina. STUDY DESIGN AND METHODS: From June 2006 to March 2007 a sample of 1455 blood donors was recruited from two blood banks in Chaco province, an area of Argentina with highly endemic T. cruzi infection. Samples were tested by three epimastigote lysate enzyme immunoassays (EIAs), one recombinant antigen EIA, two indirect hemagglutination assay (IHA) tests, a particle agglutination assay (PA), and a research trans-sialidase inhibition assay (TIA). Sensitivity and specificity were estimated using latent class analysis (LCA). RESULTS: LCA estimated the consensus prevalence of T. cruzi infection at 24.5%. Interassay correlation was higher among the four EIA tests and TIA compared to IHA tests. Assay sensitivities varied from 96 to 99.7 for different EIAs, 91% for TIA, 84% for PA, and 66 to 74% for IHA tests. Relative to the LCA, assay specificities were from 96% to almost 100%. CONCLUSION: Based on the comparison of several tests in a large population from an endemic area for T. cruzi infection, our data showed an adequate sensitivity for EIA tests in contrast to PA and IHA assays. The latter tests should no longer be used for blood donor screening.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available